Akute myeloische Leukämie: von der risikoadaptierten zur Genotyp-spezifischen Therapie

akute myeloische Leukämie - Mutationen

acute myeloid leukemia - mutations

Literatur

• 1 Arber D A, Vardiman J W, Brunning R D. et al .Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow S H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed.. Geneva: WHO; 2008
• 2 Becker H, Marcucci G, Maharry K. et al . Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures.  J Clin Oncol. 2010;  28 596-604
• 3 Burnett A K, Hills R K, Milligan D. et al . Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.  J Clin Oncol. 2011;  29 369-377
• 4 Delhommeau F, Dupont S, Della Valle V. et al . Mutation in TET2 in myeloid cancers.  N Engl J Med. 2009;  360 2289-2301
• 5 Döhner H, Estey E H, Amadori S. et al . Diagnosis and management of acute myeloid leukemia in adults.  Blood. 2010;  115 453-474
• 6 Figueroa M E, Abdel-Wahab O, Lu C. et al . Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.  Cancer Cell. 2010;  18 553-567
• 7 Juliusson G, Antunovic P, Derolf A. et al . Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.  Blood. 2009;  113 4179-4187
• 8 Koreth J, Schlenk R, Kopecky K J. et al . Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission.  JAMA. 2009;  301 2349-2361
• 9 Ley T J, Ding L, Walter M J. et al . DNMT3A mutations in acute myeloid leukemia.  N Engl J Med. 2010;  363 2424-2433
• 10 Löwenberg B, Ossenkoppele G J, van Putten W. et al . High-dose daunorubicin in older patients with acute myeloid leukemia.  N Engl J Med. 2009;  361 1235-1248
• 11 Mayer R J, Davis R B. et al . Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.  N Engl J Med. 1994;  331 896-903
• 12 Paschka P, Schlenk R F, Gaidzik V I. et al . IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.  J Clin Oncol. 2010;  28 3636-3643
• 13 Schlenk R F, Döhner K, Kneba M. et al . Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with Acute Myeloid Leukemia.  Haematologica. 2009;  94 54-60
• 14 Schlenk R F, Döhner K, Krauter J. et al . Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.  N Engl J Med. 2008;  358 1909-1918
• 15 Schlenk R F, Döhner K, Mack S. et al . Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A.  J Clin Oncol. 2010;  28 4642-4648
• 16 Schlenk R F, Ganser A, Döhner K. Prognostic and predictive effect of molecular and cytogenetic aberrations in acute myeloid leukemia.  ASCO Educational Book. http://www.asco.org 2010;  228-232
• 17 Stone R M, Fischer T, Paquette R. et al . A phase 1b study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia.  Blood. 2009;  114 634 (Abstract)
• 18 Taskesen E, Bullinger L, Corbacioglu A. et al . Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients.  Blood. 2011;  117 2469-2475